Oramed Pharmaceuticals Inc. (ORMP) EPS Estimated At $-0.30

March 14, 2018 - By Winifred Garcia

 Oramed Pharmaceuticals Inc. (ORMP) EPS Estimated At $ 0.30
Investors sentiment decreased to 2 in 2017 Q3. Its down 4.00, from 6 in 2017Q2. It dropped, as 2 investors sold Oramed Pharmaceuticals Inc. shares while 2 reduced holdings. 2 funds opened positions while 6 raised stakes. 255,973 shares or 20.44% less from 321,734 shares in 2017Q2 were reported.
The Illinois-based Gp One Trading L P has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Morgan Stanley has invested 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Wells Fargo & Mn holds 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) or 14,725 shares. Susquehanna Intl Group Ltd Liability Partnership stated it has 18,762 shares or 0% of all its holdings. Tower Ltd (Trc) reported 393 shares stake. Bancorp Of Montreal Can accumulated 1,600 shares or 0% of the stock. Plante Moran Ltd Liability Corp stated it has 300 shares or 0% of all its holdings. Pnc Service Grp Inc Inc holds 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) or 21,200 shares. United Kingdom-based Barclays Public Ltd Liability Corporation has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Renaissance Technology Ltd Limited Liability Company holds 0% or 83,000 shares. Glenmede Trust Na accumulated 0% or 20,000 shares. New York-based Jpmorgan Chase & has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Retail Bank Of America Corp De holds 1,117 shares or 0% of its portfolio. Royal Bancorp Of Canada holds 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 500 shares. 500 are owned by Jfs Wealth Limited Co.

Analysts expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report $-0.30 EPS on April, 4.They anticipate $0.06 EPS change or 25.00 % from last quarter’s $-0.24 EPS. After having $-0.18 EPS previously, Oramed Pharmaceuticals Inc.’s analysts see 66.67 % EPS growth. The stock decreased 0.21% or $0.01 during the last trading session, reaching $7.25. About 20,439 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has risen 2.79% since March 14, 2017 and is uptrending. It has underperformed by 13.91% the S&P500.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Ratings Coverage

Among 4 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals had 9 analyst reports since August 14, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of ORMP in report on Wednesday, November 22 with “Buy” rating. FBR Capital initiated it with “Outperform” rating and $15 target in Thursday, November 19 report. On Tuesday, December 1 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, October 5 report. Rodman & Renshaw initiated the shares of ORMP in report on Friday, October 2 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Thursday, October 1. The firm has “Sell” rating given on Friday, August 14 by Zacks. B. Riley & Co maintained the stock with “Buy” rating in Monday, December 11 report.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $104.19 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

More notable recent Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news were published by: Prnewswire.com which released: “Oramed Pharmaceuticals’ CEO Issues Letter to Shareholders” on January 19, 2018, also Prnewswire.com with their article: “Oramed Adds Two New Members to its Scientific Advisory Board” published on February 28, 2018, Marketwatch.com published: “Oramed Pharmaceuticals Inc.” on May 18, 2016. More interesting news about Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were released by: Seekingalpha.com and their article: “Oramed Vs. Novo Nordisk In Race For Oral GLP-1” published on November 29, 2016 as well as Seekingalpha.com‘s news article titled: “Oramed: The Atypical Biotechnology Company With Great Upside Potential” with publication date: July 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.